今日快报！博汇股份经营困境致股债双杀，转债暴跌20%

博汇股份经营困境致股债双杀，转债暴跌20%

宁波 2024年6月18日 - A股市场今日出现“股债双杀”现象，其中，博汇股份(300839)因自曝经营困难，导致股价和转债价格双双暴跌。

公司经营困难重重

博汇股份是一家主要从事芳烃系列产品研发、生产、销售的上市公司。6月13日，公司发布公告称，由于经营资金困难，公司决定对40万吨/年芳烃抽提装置、40万吨/年环保芳烃油生产装置及相关配套装置进行停产。

此次停产将对公司营业收入、现金流和经营利润产生不利影响。公司预计，2024年上半年营业收入将同比下降50%左右，净利润将由盈转亏。

税务问题雪上加霜

更令市场担忧的是，博汇股份还面临着税务问题。3月29日，公司收到国家税务总局宁波市镇海区税务局澥浦税务所《税务事项通知书》，要求公司“重芳烃衍生品”按“重芳烃”缴纳消费税。

这一要求将对公司生产重芳烃衍生品装置产生重大不利影响。如按税务通知书的要求，按重芳烃缴纳消费税，则对公司2023年年度利润影响约为3.0亿元，业绩将由盈利转为大额亏损。

股债双双暴跌

在经营困难和税务问题的双重打击下，博汇股份股价和转债价格出现大幅下跌。6月14日，公司股价跌停，报收5.43元/股，创上市以来新低；转债价格也跌停，报收73.928元/张，同样刷新上市以来最低纪录。

市场分析人士指出，博汇股份的经营困境和税务问题，加剧了市场对公司信用风险的担忧，导致股债双双暴跌。

事件对投资者启示

博汇股份事件对投资者也敲响了警钟。在投资时，投资者应仔细分析公司的财务状况、经营情况以及潜在的风险因素，避免盲目投资。同时，投资者也要注意甄别信息来源，避免被虚假信息误导。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.